196 related articles for article (PubMed ID: 19549768)
1. HPV16 tumor associated macrophages suppress antitumor T cell responses.
Lepique AP; Daghastanli KR; Cuccovia IM; Villa LL
Clin Cancer Res; 2009 Jul; 15(13):4391-400. PubMed ID: 19549768
[TBL] [Abstract][Full Text] [Related]
2. Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response.
de Vos van Steenwijk PJ; Piersma SJ; Welters MJ; van der Hulst JM; Fleuren G; Hellebrekers BW; Kenter GG; van der Burg SH
Clin Cancer Res; 2008 Nov; 14(22):7188-95. PubMed ID: 19010835
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
4. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
5. Local applications of GM-CSF induce the recruitment of immune cells in cervical low-grade squamous intraepithelial lesions.
Hubert P; Doyen J; Capelle X; Arafa M; Renoux V; Bisig B; Seidel L; Evrard B; Bousarghin L; Gerday C; Boniver J; Foidart JM; Delvenne P; Jacobs N
Am J Reprod Immunol; 2010 Aug; 64(2):126-36. PubMed ID: 20367631
[TBL] [Abstract][Full Text] [Related]
6. Regulatory (FOXP3+) T cells as target for immune therapy of cervical intraepithelial neoplasia and cervical cancer.
Loddenkemper C; Hoffmann C; Stanke J; Nagorsen D; Baron U; Olek S; Huehn J; Ritz JP; Stein H; Kaufmann AM; Schneider A; Cichon G
Cancer Sci; 2009 Jun; 100(6):1112-7. PubMed ID: 19514119
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth.
Bolpetti A; Silva JS; Villa LL; Lepique AP
BMC Immunol; 2010 Jun; 11():27. PubMed ID: 20525400
[TBL] [Abstract][Full Text] [Related]
8. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.
Ramos CA; Narala N; Vyas GM; Leen AM; Gerdemann U; Sturgis EM; Anderson ML; Savoldo B; Heslop HE; Brenner MK; Rooney CM
J Immunother; 2013 Jan; 36(1):66-76. PubMed ID: 23211628
[TBL] [Abstract][Full Text] [Related]
10. IL-17 suppresses immune effector functions in human papillomavirus-associated epithelial hyperplasia.
Gosmann C; Mattarollo SR; Bridge JA; Frazer IH; Blumenthal A
J Immunol; 2014 Sep; 193(5):2248-57. PubMed ID: 25063870
[TBL] [Abstract][Full Text] [Related]
11. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations.
Cheng WF; Lee CN; Su YN; Chang MC; Hsiao WC; Chen CA; Hsieh CY
Immunology; 2005 May; 115(1):136-49. PubMed ID: 15819706
[TBL] [Abstract][Full Text] [Related]
12. HPV-16 E7-Specific Cellular Immune Response in Women With Cervical Intraepithelial Lesion Contributes to Viral Clearance: A Cross-Sectional and Longitudinal Clinical Study.
Zhang L; Shi X; Zhang Q; Mao Z; Shi X; Zhou J; Jian A; Zhu R; Jiang S; Lu W
Front Immunol; 2021; 12():768144. PubMed ID: 35095843
[TBL] [Abstract][Full Text] [Related]
13. Correlation of E6 and E7 levels in high-risk HPV16 type cervical lesions with CCL20 and Langerhans cells.
Jiang B; Xue M
Genet Mol Res; 2015 Sep; 14(3):10473-81. PubMed ID: 26400278
[TBL] [Abstract][Full Text] [Related]
14. Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design.
Grabowska AK; Kaufmann AM; Riemer AB
Int J Cancer; 2015 Jan; 136(1):212-24. PubMed ID: 24824905
[TBL] [Abstract][Full Text] [Related]
15. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix.
Santin AD; Bellone S; Palmieri M; Bossini B; Roman JJ; Cannon MJ; Bignotti E; Canè S; Pecorelli S
Gynecol Oncol; 2003 May; 89(2):271-80. PubMed ID: 12713991
[TBL] [Abstract][Full Text] [Related]
16. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
[TBL] [Abstract][Full Text] [Related]
17. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
Li YL; Qiu XH; Shen C; Liu JN; Zhang J
Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
[TBL] [Abstract][Full Text] [Related]
18. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer.
Piersma SJ; Jordanova ES; van Poelgeest MI; Kwappenberg KM; van der Hulst JM; Drijfhout JW; Melief CJ; Kenter GG; Fleuren GJ; Offringa R; van der Burg SH
Cancer Res; 2007 Jan; 67(1):354-61. PubMed ID: 17210718
[TBL] [Abstract][Full Text] [Related]
19. CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend.
Kim KH; Greenfield WW; Cannon MJ; Coleman HN; Spencer HJ; Nakagawa M
Cancer Immunol Immunother; 2012 Jan; 61(1):63-70. PubMed ID: 21842207
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]